Cardio-Protection Against Cancer Treatment-Related Cardiac Dysfunction: Who is at Risk?

Macedo, Ariane Vieira Scarlatelli; Martins, Wolney de Andrade

ABC Heart Fail Cardiomyop 2022; 2(4): 333-334

Cardio-Protection Against Cancer Treatment-Related Cardiac Dysfunction: Who is at Risk?

Ariane Vieira Scarlatelli Macedo , Wolney de Andrade Martins

DOI: 10.36660/abchf.20230006

Long-term survival of cancer patients has improved, and the sequelae of treatment have become more evident. Mortality rates of cancer patients, adjusted for age, have decreased globally, with a reduction by 17% from 1990 to 2019.

The prevention of left ventricular dysfunction secondary to cancer treatment is still a medical challenge. Drug-induced cardiotoxicity is the main limiting factor for the administration of higher doses of anthracyclines. Addressing the anthracycline-induced cardiotoxicity is particularly important for pediatric cancer survivors, as it remains one of the main causes of morbidity and mortality in this population.